Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir plus daclatasvir or ravidasvir in Egyptian adults with COVID-19
ISRCTN21085622Phase 3Completed
- Sponsor
- European Egyptian Pharmaceutical Industries
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sofosbuvir, ravidasvir and daclatasvir in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by European Egyptian Pharmaceutical Industries. Primary endpoints: Sum of counted symptoms without deterioration and Mean oxygen saturation. Started Sep 2020; status: completed.
02
Drugs
sofosbuvirravidasvirdaclatasvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN21085622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN21085622.